Virax Biolabs Group Limited (VRAX)
NASDAQ: VRAXHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
VRAX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $446.40K
- EPS (TTM)
- -$12.64
- Dividend yield
- None
- 52-week range
- 0.293 – 21.75
- Day range
- 0.3287 – 0.3696
- Volume / Avg
- 85.67K / 360.62K
- Beta
- —
- Shares outstanding
- 1.34M
52-week range
VRAX stock today
Shares of Virax Biolabs Group (VRAX) finished lower on Nov 20 at $0.3319, a drop of 12.89% or $0.0491 per share, versus the S&P 500's 3.70% decline. Trading was light, with 85.67K shares changing hands, about 24% of the average daily volume. Shares are 98.5% below their 52-week high of $21.75 and 13.3% above the 52-week low of $0.293, near the bottom of the past year's range.
Virax Biolabs Group has posted a net loss over the last twelve months (EPS of -$12.64), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Virax Biolabs Group
Company profileVirax Biolabs Group Limited, a biotechnology company, focuses on immune response detection, T cell immune profiling, and the development of in vitro diagnostic technologies for viral and immune-mediated diseases in the United Kingdom, the United States, and China. The company offers ViraxImmune, a T cell-based immune profiling and diagnostic platform for post-acute infection syndromes, including long COVID, myalgic encephalomyelitis / chronic fatigue syndrome, and post-treatment Lyme disease. It also provides ImmuneSelect, a research-use-only portfolio of peptide pool ELISpot plates and related immune reagents.
- Sector
- Health Care
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- CEO
- Mr. James Foster
- Headquarters
- Lanarkshire
- Employees
- 26
- IPO year
- 2022
- Website
- viraxbiolabs.com
Financial highlights
Full financialsIn fiscal 2025, Virax Biolabs Group generated $6,331 in revenue, down 96.0% from fiscal 2024, its first annual decline since 2022. Virax Biolabs Group reported a net loss of $6.1 million, compared with a loss of $6.7 million a year earlier. Gross margin was -838.2% (down from 32.3%) and operating margin -97344.8%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $6.33K | $156.42K | $8.56K | $0 | $123.82K |
| Growth | -95.95% | +1727.11% | — | -100.00% | — |
| Net income | $-6.06M | $-6.73M | $-5.46M | $-1.71M | $-650.98K |
| EPS (diluted) | $-1.62 | $-3.36 | $-5.13 | $-1.79 | — |
VRAX news
All VRAX newsVirax Biolabs Group peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| QCLSQ/C Technologies Inc. | 0.2784 | -6.01% | $2.40M | vs VRAX |
| CDIOCardio Diagnostics Holdings Inc. | 1.60 | -3.03% | $4.74M | vs VRAX |
| BMRABiomerica Inc. | 1.08 | -0.92% | $4.97M | vs VRAX |
| TRIBTrinity Biotech plc ADR | 6.24 | +13.76% | $5.07M | vs VRAX |
| VNRXVolitionRX Limited | 0.1621 | -1.58% | $5.85M | vs VRAX |
| IMDXInsight Molecular Diagnostics Inc. | 1.97 | +18.67% | $80.88M | vs VRAX |
| ICCCImmuCell Corporation | 10.92 | -2.41% | $99.28M | vs VRAX |
| NNNNAnbio Biotechnology Class A | 3.32 | -9.04% | $145.72M | vs VRAX |
Indexes, lists and sector
Virax Biolabs Group stock FAQ
What is Virax Biolabs Group's stock price today?
VRAX last traded at $0.3319 as of Nov 20, 4:00 PM EST, down 12.89% on the day. Prices are delayed at least 15 minutes.
Who is Virax Biolabs Group's CEO?
Mr. James Foster is the chief executive officer of Virax Biolabs Group Limited, which has about 26 employees.
What is the VRAX 52-week high?
The 52-week high for VRAX is $21.75 and the 52-week low is $0.293. The stock is currently 98.5% below its high.